Editorial: Research on the correlative mechanisms and clinical exploration of headache and cerebrovascular diseases
Assessing directional connections between symptoms, cognition, insight, and real-life functioning in schizophrenia: a partial ancestor graphs analysis
Romanian male patients with the dual diagnosis of schizophrenia and alcohol use disorder: a prospective study of clinical, social, and treatment-related factors affecting quality of life
Internalizing and externalizing pathways to internet gaming disorder: the roles of anger and social anxiety
Perception of social support and psychological well-being among mothers of individuals with intellectual disabilities: the mediating role of self-efficacy
From cats to cortex: T. gondii and psychosis, depression, and anxiety
STAT+: Drug meant to make gene therapy safer may also make it less effective
BOSTON — A medicine increasingly used to mitigate the risk of deadly gene therapy side effects could also blunt the therapy’s effectiveness, a new study finds.
The trial, from the startup Encoded Therapeutics, tested a gene therapy for Dravet syndrome, a severe form of genetic epilepsy. A key concern in gene therapy trials is that patients could mount an immune response against the engineered viruses used to deliver new genes into the brain.
In the study, Encoded assigned most of the 21 children in the trial to receive steroids, the most commonly used immune suppressant. A subset — including most of the patients on the highest dose level — were assigned to also receive sirolimus, also known as rapamycin, a drug historically given to prevent rejection in transplant recipients.
Psychosocial Effects of a Trauma-Informed Artificial Intelligence-Supported Chatbot in Adults Newly Diagnosed With Cancer
Interventions: Other: Trauma-Informed AI-Supported Chatbot
Sponsors: Koç University; The Scientific and Technological Research Council of Turkey
Not yet recruiting

